| Title | MINIREVIEW] Cure of tuberculosis using nanotechnology: An overview |
|---|---|
| Author | Rout George Kerry1, Sushanto Gouda2, Bikram Sil1, Gitishree Das3, Han-Seung Shin4*, Gajanan Ghodake5, and Jayanta Kumar Patra3* |
| Address | 1Department of Biotechnology, AMIT College, Khurda 752057, Odisha, India, 2Amity Institute of Wildlife Science, Amity University, Noida 201313, Uttar Pradesh, India, 3Research Institute of Biotechnology & Medical Converged Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea, 4Department of Food Science and Biotechnology, Dongguk University-Seoul, Goyang 10326, Republic of Korea, 5Department of Biological and Environmental Science, College of Life Science and Biotechnology, Dongguk University-Seoul, Goyang 10326, Republic of Korea |
| Bibliography | Journal of Microbiology, 56(5),287–299, 2018, |
| DOI | 10.1007/s12275-018-7414-y |
| Key Words | tuberculosis, Mycobacterium tuberculosis, infectious diseases, proteomics, genomics, nano-medicine |
| Abstract | Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a major health issue of the present era. The bacterium inhabits the host macrophage and other immune cells where it modulates the lysosome trafficking protein, hinders the formation of phagolysosome, and blocks the TNF receptor- dependent apoptosis of host macrophage/monocytes. Other limitations such as resistance to and low bioavailability and bio-distribution of conventional drugs aid to their high virulence and human mortality. This review highlights the use of nanotechnology-based approaches for drug formulation and delivery which could open new avenues to limit the pathogenicity of tuberculosis. Moreover phytochemicals, such as alkaloids, phenols, saponins, steroids, tannins, and terpenoids, extracted from terrestrial plants and mangroves seem promising against M. tuberculosis through different molecular mechanisms. Further understanding of the genomics and proteomics of this pathogenic microbe could also help overcome various research gaps in the path of developing a suitable therapy against tuberculosis. |